▼ Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the 
treatment of symptomatic chronic heart failure in adults with reduced ejection 
fraction.(1) It is described as an angiotensin receptor neprilysin inhibitor and 
contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor 
antagonist, valsartan.(1-3) Here, we review the evidence for sacubitril 
valsartan and consider its place in the management of heart failure.